SLC5A2 and type 2 diabetes mellitus: All SGLT‐2 inhibitors showed remarkable and similar improvements of HHF in their corresponding CVOTs in T2DM, ranging from 33%31 to 39%20 (canagliflozin) over 27% (dapagliflozin)32 to 35% (empagliflozin)33 improvement of HHF and across the spectrum of renal disease with eGFRs from > 30 ml/min/1.73m2 to > 90 ml/min/1.73 m2.76, 77